Welcome to the Lilly Scientific Information Page for AAD 2026
American Academy of Dermatology
Denver, Colorado
Quicklinks
https://lillyinvestigatorresearch.com
To stay informed on the latest science and innovation, please be sure to follow us on Twitter/X
To stay informed on the latest science and innovation from Lilly Medical, please be sure to follow us on LinkedIn
Disclosures
FRIDAY
- Disease State: Obesity & Psoriasis
- Molecule(s): Ixekizumab
Psoriasis Patients with Overweight and Obesity Have Higher Relative Risk of Psoriatic Arthritis, Asthma, and Cardiometabolic Disorders
Trial(s) Overview:
Not Applicable
FRIDAY
FRIDAY
- Disease State: Psoriasis
- Molecule(s): Ixekizumab
Ixekizumab Demonstrates Effectiveness in Reducing the Severity of Musculoskeletal Symptoms in Patients with Psoriasis, Without Reported Psoriatic Arthritis: Results from the Psoriasis in Special Areas (PSoSA) Study
Trial(s) Overview:
PSoSA
FRIDAY
- Disease State: Dermatitis
- Molecule(s): Lebrikizumab
Top Reasons for Initiating Lebrikizumab in Adolescents with Moderate-To-Severe Atopic Dermatitis: A US Real-World Survey
Trial(s) Overview:
Real World Evidence
FRIDAY
- Disease State: Dermatitis
- Molecule(s): Lebrikizumab
Lebrikizumab Rapidly Improves Head, Neck and Face Atopic Dermatitis in Adults and Adolescents with Skin of Color in ADmirable
Trial(s) Overview:
FRIDAY
- Disease State: Dermatitis
- Molecule(s): Lebrikizumab
Lebrikizumab Clinical Responses in Eczema Area and Severity Index Clinical Signs Across Body Regions in Patients with Moderate-to-Severe Atopic dermatitis Who Required Longer Than 16 Weeks to Reach EASI 75 or IGA 0/1 in Two Randomized Controlled Cinical Trials
Trial(s) Overview:
FRIDAY
- Disease State: Perennial Allergic Rhinitis (PAR)
- Molecule(s): Lebrikizumab
Lebrikizumab from Skin to Airways: Comorbid Allergic Rhinitis in Patients with Atopic Dermatitis and the PREPARED-1 Perennial Allergic Rhinitis Trial Design
Trial(s) Overview:
FRIDAY
- Disease State: Psoriasis
- Molecule(s): Ixekizumab
Ixekizumab Demonstrates Continued Improvements in Nail and Scalp Psoriasis through 52 Weeks: Final Results from the Psoriasis in Special Areas (PSoSA) Study
Trial(s) Overview:
PSoSA
FRIDAY
- Disease State: Dermatitis
- Molecule(s): Lebrikizumab
Exposure-Response Modeling Predicted Long-Lasting Responses with Lebrikizumab Every 8 Week Maintenance Dosing for Moderate-to-Severe Atopic Dermatitis And Aligned with Observed Clinical Trial Data
Trial(s) Overview:
Not Applicable
FRIDAY
- Disease State: Alopecia Areata
- Presented by: Amy McMichael
- Molecule(s): Baricitinib
Examining Effectiveness of Baricitinib Therapy in Black patients with Alopecia Areata: Observations from an Open Label Study Addendum to BRAVE-AA1
Trial(s) Overview:
BRAVE-AA1
SATURDAY
- Disease State: Obesity & Psoriatic Arthritis
- Presented by: Joseph Merola
- Molecule(s): Ixekizumab
Concomitant Therapy with Ixekizumab Plus Tirzepatide in Adults with Psoriatic Arthritis and Overweight or Obesity Demonstrated Superior Disease Control Compared to Ixekizumab Alone: Results from the Ph3b TOGETHER-PsA Trial
Trial(s) Overview:
SATURDAY
- Disease State: Alopecia Areata
- Presented by: Justin Ko
- Molecule(s): Baricitinib
Real-World Effectiveness of Baricitinib for Severe Alopecia Areata by Baseline Hair Loss and Episode Duration: Results from a Prospective Observational Study
Trial(s) Overview:
Real World Evidence
SATURDAY
- Disease State: Dermatitis
- Presented by: Seemal Desai
- Molecule(s): Lebrikizumab
Lebrikizumab Improves a Diverse Array of Atopic Dermatitis Clinical Features Found in Patients with Skin of Color
Trial(s) Overview:
To receive the latest science and innovation from LillyMedical, be sure to follow us via our Twitter handle @LillyMedical. See our community guidelines.
Contact Us
Call us
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)